← Leaderboards
Dennis E. Hruby
Oregon State University
$27,079,231
Attributed
$29,006,698
Total exposure
15
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $8.6M · FY2005–15$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
Funding mix
By agency
NIH$29,006,698 · 15
By mechanism
R44$8,350,256 · 3
N01$8,348,051 · 1
R01$7,899,318 · 2
R43$2,720,076 · 5
R21$1,095,435 · 2
U01$567,562 · 1
Top collaborators
- Chelsea Byrd Olsen3 shared
Most similar at Oregon State University
Same institution · by research overlap
- David A. Horne$4,611,324
- William D Smart$1,093,774
Others in their field
Top investigators on “Antiviral Agents”
- Constance Ann Benson · University Of California, San Diego$209,152,068
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$120,325,769
- Judith S. Currier · University Of California Los Angeles$102,391,456
- Beth Baseler · Leidos Biomedical Research, Inc.$83,440,795
- Sharon A Nachman · Johns Hopkins University$77,262,665
- John Damon Chodera · Sloan-Kettering Inst Can Research$58,660,403
Research focus
Antiviral AgentsTissue /Cell CultureDrug Design /Synthesis /ProductionVirus ReplicationViralBioterrorism /Chemical WarfareHigh Throughput TechnologyAnalogVaccinia VirusDrug ResistanceVirulenceSmall MoleculeEquilibriumEvaluationDengueBiodefenseExcretory FunctionHigh Throughput ScreeningBaseDrug KineticsFaceAntibody-Dependent EnhancementBiologicalDisease Outbreaks
Grant awards (32)
Antiviral therapeutics for flavivirus infections$1,192,443
R01 · FY2015 · AI · contact PI
Antiviral therapeutics for flavivirus infections$1,246,033
R01 · FY2014 · AI · contact PI
Antiviral therapeutics for flavivirus infections$1,152,093
R01 · FY2013 · AI
Antiviral therapeutics for flavivirus infections$1,260,044
R01 · FY2012 · AI
Antiviral therapeutics for flavivirus infections$1,442,798
R01 · FY2011 · AI
Novel small molecule inhibitors of dengue replication$559,265
R43 · FY2009 · AI · contact PI
Novel small molecule inhibitors of dengue replication$404,472
R43 · FY2008 · AI · contact PI
Enhancing the immune response to antigens delivered by the bacterial vector, Stre$280,538
R43 · FY2008 · AI · contact PI
DEVELOPMENT OF THERAPEUTIC AGENT FOR SELECTED VIRAL DISAESES$8,348,051
N01 · FY2007 · AI · contact PI
Enhancing the immune response to antigens delivered by the bacterial vector, Stre$273,956
R43 · FY2007 · AI · contact PI
Bacterial Commensal Vector Delivery/Smallpox Vaccine$491,430
R43 · FY2006 · AI · contact PI
Pox Proteomics$270,075
R21 · FY2006 · AI · contact PI
Antiviral Drugs for Category A Arenavirus$3,214,689
R44 · FY2005 · AI
BIOLOGY OF VACCINIA VIRUS ACYLPROTEINS$279,552
R01 · FY2005 · AI
Variola Virus G1L:An Antiviral Drug Target$275,196
R21 · FY2005 · AI
Pox Proteomics$274,595
R21 · FY2005 · AI
Small Molecule Inhibitors of Smallpox Virus Replication$2,177,971
R44 · FY2004 · AI
Antiviral Drugs for Category A Arenavirus$2,092,539
R44 · FY2004 · AI
BIOLOGY OF VACCINIA VIRUS ACYLPROTEINS$279,552
R01 · FY2004 · AI
Variola Virus G1L:An Antiviral Drug Target$275,569
R21 · FY2004 · AI
Antiviral Drugs Against Hemorrhagic Fever Viruses$495,751
R43 · FY2003 · AI
DegP Proteinase Inhibitors: Novel Anti-Infectives$335,698
R44 · FY2003 · AI
BIOLOGY OF VACCINIA VIRUS ACYLPROTEINS$279,552
R01 · FY2003 · AI
Small Molecule Inhibitors of Smallpox Virus Replication$214,664
R43 · FY2003 · AI
DegP Proteinase Inhibitors: Novel Anti-Infectives$529,359
R44 · FY2002 · AI
BIOLOGY OF VACCINIA VIRUS ACYLPROTEINS$279,552
R01 · FY2002 · AI
DEVELOPMENT OF POXVIRUS PROTEINASE INHIBITORS$172,704
U01 · FY2002 · AI
BIOLOGY OF VACCINIA VIRUS ACYLPROTEINS$262,922
R01 · FY2001 · AI
DEVELOPMENT OF POXVIRUS PROTEINASE INHIBITORS$183,454
U01 · FY2001 · AI
BIOLOGY OF VACCINIA VIRUS ACYLPROTEINS$224,777
R01 · FY2000 · AI
DEVELOPMENT OF POXVIRUS PROTEINASE INHIBITORS$211,404
U01 · FY2000 · AI
NOVEL ANTI-INFECTIVES TO COMBAT RESISTANT STAPHYLOCOCCUS$26,000
RC1 · FY2000 · AI